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AbstrAct
Ulcerative colitis (UC) is a chronic disease, in which the lining of the colon 
becomes inflamed and develops ulcers leading to abdominal pain, diarrhea, and rectal 
bleeding. The extent of these symptoms depends on disease severity. The protein 
arginine deiminase (PAD) family of enzymes converts peptidyl-Arginine to peptidyl-
Citrulline through citrullination. PADs are dysregulated, with abnormal citrullination 
in many diseases, including UC and colorectal cancer (CRC). We have developed the 
small molecule, pan-PAD inhibitor, Chlor-amidine (Cl-amidine), with multiple goals, 
including treating UC and preventing CRC. Building off our recent results showing 
that: 1) Cl-amidine suppresses colitis in vivo in a dextran sulfate sodium (DSS) mouse 
model; and 2) Cl-amidine induces microRNA (miR)-16 in vitro causing cell cycle arrest, 
we tested the hypothesis that Cl-amidine can prevent tumorigenesis and that miR-16 
induction, by Cl-amidine, may be involved in vivo. Consistent with our hypothesis, 
we present evidence that Cl-amidine, delivered in the drinking water, prevents colon 
tumorigenesis in our mouse model of colitis-associated CRC where mice are given 
carcinogenic azoxymethane (AOM), followed by multiple cycles of 2% DSS to induce 
colitis. To begin identifying mechanisms, we examined the effects of Cl-amidine on 
miR-16. Results show miR-16 suppression during the colitis-to-cancer sequence in 
colon epithelial cells, which was rescued by drinking Cl-amidine. Likewise, Ki67 and 
cellular proliferation targets of miR-16 (Cyclins D1 and E1) were suppressed by Cl-
amidine. The decrease in cell proliferation markers and increase in tumor suppressor 
miRNA expression potentially define a mechanism of how Cl-amidine is suppressing 
tumorigenesis in vivo. 
IntroductIon
Ulcerative colitis (UC) is a chronic, relapsing 
inflammatory bowel disease that affects millions of 
people worldwide and causes symptoms of abdominal 
pain, diarrhea, and rectal bleeding. Due to the chronic 
inflammatory state of UC, which causes cyclical oxidative 
stress and leads to DNA damage, patients with UC are 
at a higher risk of developing colorectal cancer (CRC) 
[1]. The probability of developing CRC increases yearly 
once UC develops, with up to an approximate 20% 
incidence after 30 years [1, 2]. Current treatment options 
help to treat the symptoms, prevent flares, and heal the 
damaged colon; however, the treatment outcomes are 
often marginal, patients become refractory, and there are 
dangerous adverse side effects. Therefore, we continue to 
investigate novel therapies showing reduced toxicity and 
more substantial efficacy in treating UC and preventing 
CRC.
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The protein arginine deiminase (PAD) family of 
enzymes converts peptidyl-Arginine to peptidyl-Citrulline 
through a process called ‘citrullination’ [3]. There are five 
isozymes found in mammals (PAD1-4 and 6), with 70-
95% homology in their amino acid sequence [4]. The PAD 
isozymes are encoded by a cluster of homologous genes 
found on Chromosome 1 in humans [4, 5]. Citrullination 
can affect protein-protein interactions, hydrogen bond 
formation, and protein structure due to the shift from 
the positively charged peptidyl-Arginine to the neutral 
peptidyl-Citrulline [5]. At physiological activity levels, 
PADs regulate many cell signaling pathways including 
differentiation, apoptosis, and gene transcription [6]. 
However, over the past decade, it is becoming increasingly 
apparent that aberrant PAD activity is involved in many 
human inflammatory diseases such as: rheumatoid 
arthritis, Alzheimer’s disease, and multiple sclerosis [3, 
7-10]. Concerning our study, PADs, especially PAD4, are 
found to be dysregulated in UC and CRC [11-14]. In UC 
and other chronic inflammatory, autoimmune diseases, it 
is thought that the accumulation of citrullinated proteins is 
what leads to an abnormal immune response that further 
exacerbates the inflammatory response [6]. 
We have developed a novel, small molecule 
inhibitor of PADs, named N-α-benzoyl-N5-(2-chloro-
1-iminoethyl)-L-ornithine amide or Chlor-amidine (Cl-
amidine). Cl-amidine prevents citrullination by covalently 
modifying a conserved cysteine residue in the active site 
of the PADs, causing irreversible inactivation of the 
enzyme [6]. Cl-amidine is an excellent candidate drug 
for our CRC prevention studies because it: 1) exhibits 
little toxicity at doses we use here in vitro and in vivo; 2) 
displays no immunosuppressive effects in multiple disease 
models associated with PAD dysregulation; 3) effectively 
suppresses colitis in mice when given by oral gavage; and 
4) increases tumor suppressor microRNA (miRNA) levels 
in vitro [14-17]. Based on these precedents, we tested the 
hypothesis that Cl-amidine can prevent tumorigenesis in 
the azoxymethane (AOM)/dextran sulfate sodium (DSS) 
mouse model of colitis-associated CRC. Mechanistic 
insight is also gained by examining the levels of miRNA 
changes during this process. 
results
cl-amidine suppresses AoM/dss-induced 
tumorigenesis in mice
To ensure that 2% DSS was effectively causing 
colitis in the treated mice, we determined the histology 
score of four euthanized mice (per group) at day 35. 
In Figure 1B, histology scores for ulceration and 
inflammation indicate that the AOM + DSS only group 
does have a significantly higher score than the AOM only 
group. As expected at this time point, despite the varying 
severity of colitis in the treatment groups, none of the mice 
had developed tumors.
At day 70, mice were euthanized, and we recorded 
the number mice with tumors (Table 1) and the average 
number of tumors per mouse in each group (Figure 2A; 
tumor multiplicity). We also measured the size of each 
tumor (Table 1) and captured representative images 
of the methylene blue stained colons (Figure 2B). No 
tumors were found in the control AOM only mice and, 
as predicted, the AOM + DSS only group (Group 2: 2.8 
± 0.68 tumors/animal) had the highest tumor multiplicity. 
Mice treated with Cl-amidine (Group 3: 0.07 ± 0.07 
tumors/animal; Group 4: 0.67 ± 0.23 tumors/animal) had 
significantly reduced tumor multiplicity than the AOM 
+ DSS only group. Interestingly, there was a significant 
table 1:tumor incidence, multiplicity, and size are reduced in the colons of mice treated with cl-amidine.  
tumor Incidence Average # of tumors
Average tumor 
multiplicity <1mm
Average tumor 
multiplicity >1mm
AOM 0 (0%) 0 0 ± 0* 0 ± 0***
AOM + DSS 13 (86.7%) 2.80 0.67 ± 0.37 2.13 ± 0.53
AOM + DSS + 0.05mg/ml 
Cl-amidine 1 (7.1%) 0.07 0 ± 0* 0.07 ± 0.07***
AOM + DSS + 0.25mg/ml 
Cl-amidine 7 (46.7%) 0.67 0 ± 0* 0.67 ± 0.23*
Tumor incidence (the number of mice per group with tumors) is shown alongside the percentage of mice with tumors. 
The average number of tumors per mouse (tumor multiplicity) is shown and is also divided based on size (<1 mm and 
>1 mm at the largest dimension).  Tumor multiplicity based on tumor size is given as mean ± standard error of the 
mean (SE).  Significant differences from the AOM + DSS only group are indicated by * (p<0.05) and *** (p<0.005).
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difference in tumor multiplicity (p < 0.05) between the 
Cl-amidine treated groups where the higher dosage group 
(Group 4: 0.25 mg/mL Cl-amidine) had a higher tumor 
multiplicity than the lower dosage group (Group 3: 0.05 
mg/mL Cl-amidine). Although at this point we are unable 
to explain this observation, perhaps a certain basal level 
of citrullination is necessary to carry out functions, such 
as apoptosis. Since the citrullination of proteins involved 
in apoptosis (e.g. vimentin, nucleophosmin, nuclear lamin 
C) facilitates the process of apoptosis [18-21], the higher 
dose of Cl-amidine may be inhibiting the citrullination 
necessary for the progression of apoptosis and aiding 
in the development of tumors, thus accounting for the 
increased tumor incidence. Nevertheless, the overall 
results from this model show for the first time that Cl-
amidine is capable of preventing tumorigenesis associated 
with chronic colitis.
cl-amidine increases mir-16 expression and 
downregulates cell proliferative mir-16 targets 
in mice
We have previously shown that Cl-amidine increases 
miR-16 expression in a p53-dependent manner resulting 
in a cell cycle arrest in vitro [17]. Since the inhibition 
of cell proliferation is a goal of many anti-cancer drug 
therapies, we hypothesized that Cl-amidine is preventing 
tumorigenesis by increasing miR-16 expression in vivo. 
To test this, we measured miR-16 expression levels in 
isolated colon epithelial (CD45-) cells at day 35 (see 
methods). We chose to investigate the miR-16 expression 
levels at the day 35 time point because we were interested 
in the mechanism preventing tumorigenesis at day 70. 
Figure 3 shows the relative fold change in miR-16 levels 
Figure 1: A. Outline of the AOM/DSS mouse model of colorectal cancer used in this study. b. Histology scoring of colon tissue samples 
from the AOM/DSS model of colon cancer at 35 days. Mice from each group were euthanized at day 35 and day 70 as described in the 
methods. Colons were harvested and processed to determine the histology score at day 35. Values represent the mean ± SE. Representative 
H&E stained colon sections (100x magnification) are shown for each group. Arrows indicate areas of inflammation. Significant differences 
from the AOM + DSS only group are indicated by * (p < 0.05) and ** (p < 0.01).
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Figure 2: tumor multiplicity is reduced in the colons of mice treated with cl-amidine. Mice from each group were euthanized 
at day 70 as described in the methods. Colons were removed and cut longitudinally. A. Tumor multiplicity in the AOM/DSS model of colon 
cancer at 70 days. Significant differences from the AOM + DSS only group are indicated by *** (p < 0.005). b. Representative methylene 
blue stained colons are shown for each group. Arrows indicate tumors. 
Figure 3: Mir-16 expression is increased in the colon epithelial cells of mice treated with cl-amidine. Mice from each 
group were euthanized at day 35 and colons were removed to be processed to separate the colon inflammatory cells from the epithelial 
cells via magnetic microbeads. Then, as described in the methods, total RNA was extracted and primed to measure miR-16 expression 
using qPCR. MiR-16 expression across the treatment groups was quantified as the relative fold change as compared to AOM only. MiR-16 
expression in colon epithelial (CD45-) cells at day 35 in the AOM/DSS model of colon cancer is shown. Significant differences from the 
AOM + DSS only group are indicated by * (p < 0.05) and *** (p < 0.005).
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in the epithelial cells. Consistent with our previously 
published in vitro data [17] and our current hypothesis, 
miR-16 expression in the AOM + DSS only group was 
significantly lower than the AOM only group and both 
Cl-amidine treated groups. Furthermore, the lower level 
of miR-16 expression in epithelial cells from the higher 
dosage group (0.25 mg/mL Cl-amidine), compared to the 
lower dosage group (0.05 mg/mL Cl-amidine), is highly 
suggestive of a direct correlation between the expression 
level of miR-16 and tumor incidence; however, the cause 
of this variability between Cl-amidine treatment groups is 
currently unknown.
miR-16 has multiple cell proliferation targets, such 
as Cyclin D1 and Cyclin E1; supporting the premise that 
it is a tumor suppressor miRNA [17, 22-25]. If miR-
16 expression is increased with Cl-amidine treatment 
(Figure 3), then we expect to see the downregulation of 
these cell proliferation targets of miR-16. Indeed, we 
confirmed that protein expression of Cyclins D1 and E1 
was suppressed in the Cl-amidine treated groups when 
compared to the AOM + DSS only group (Figures 4A and 
4B). To further verify the repression of cell proliferation 
in the mice treated with Cl-amidine, we performed IHC 
staining for the cell proliferation marker, Ki67, in colons 
Figure 4: cell proliferation proteins (cyclin d1, cyclin e1, and Ki67) are downregulated in mice treated with cl-
amidine. Colons from 4 mice per group were euthanized at day 35 and processed for IHC analysis. IRS of colons at day 35 stained with 
A. Cyclin D1, b. Cyclin E1, both known targets of miR-16, and c. Ki-67, a cell proliferation marker. Representative sections of stained 
colons (400x total magnification) are shown. Significant differences from the AOM + DSS only group are indicated by * (p < 0.05), ** (p 
< 0.01), and *** (p < 0.005). 
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collected at day 35 (Figure 4C). In the colons collected 
at day 35, the IRS of the AOM + DSS only groups were 
significantly higher than the control AOM only groups 
(Figure 4A-4C). For Cyclin D1 and Ki-67 stained colon 
sections, the lower dose Cl-amidine group (0.05 mg/
mL) had a lower IRS than the AOM + DSS only group; 
however, the group receiving 0.25 mg/mL Cl-amidine was 
not significantly lower. Interestingly, the IRS values of 
Cyclin D1 and Ki67 staining at day 35 revealed a similar 
trend to the tumor incidence and miR-16 expression 
levels in colon epithelial cells. For Cyclin E1 stained 
colon sections, the groups treated with Cl-amidine both 
had lower IRS values than the AOM + DSS only group, 
but the lower dose Cl-amidine group (0.05 mg/mL) was 
not significantly less. These results are consistent with the 
hypothesis that Cl-amidine is suppressing tumorigenesis 
in our mouse model by inhibiting cell proliferation via 
increased miR-16 expression.
dIscussIon
In this study, we provide evidence that Cl-amidine, 
a small molecule inhibitor of PADs, administered to 
mice in drinking water suppresses colitis (Figure 1) 
and tumorigenesis (Figure 2; Table 1). To uncover the 
mechanism by which Cl-amidine is acting, we revealed 
that Cl-amidine increases miR-16 expression in colon 
epithelial cells (Figure 3). Likewise, Cl-amidine treatment 
decreases protein expression of the miR-16 targets, 
Cyclins D1 and E1, and the cell proliferation marker, 
Ki67 (Figure 4). Figure 5 depicts the unique mechanism 
by which Cl-amidine prevents the tumorigenesis of CRC 
in our mouse model.
PADs are calcium-dependent. Therefore, they are 
usually inactive under physiological levels (10-8 to 10-6 M); 
and only activating during certain events (i.e. apoptosis 
and terminal epidermal differentiation) where calcium 
levels are above physiological concentrations [5, 18]. 
Interestingly, and important to this study, patients with 
active Crohn’s disease or UC have moderately higher 
Ca2+ levels than healthy controls [26]. Not surprisingly, 
then, citrullination (the post-translationally modified 
product of active PADs) is elevated in colitis [27]. During 
apoptosis and terminal epidermal differentiation, PADs are 
found to citrullinate structural proteins, such as vimentin 
and filaggrin, causing partial unfolding of the proteins 
[5, 18]. The citrullination of these structural proteins 
promotes the overall degradation of the cells during cell 
death. PADs, specifically PAD4, have also been found 
to regulate gene expression [28-33]. Many of the genes 
that the PADs regulate are involved in the progression 
of the p53 pathway, including ING4, p300, and HDAC2 
[30-32]. With the involvement of PADs in pathways 
that are crucial for proper cell growth and cell death, it 
is readily apparent that aberrant PAD activity can lead to 
deleterious consequences (e.g. abnormal DNA damage 
repair response, protein misfolding, protein inactivation). 
Additionally, citrullination controls the expression 
of tumor suppressing miRNAs. miRNAs are regulators of 
genes that control various cell signaling processes, such as 
cell proliferation, apoptosis and stress response [34]. As 
a result of an inflammatory response, such as that of UC, 
miRNAs can be altered and expression levels can fluctuate 
[35]. Although other miRNAs have been found associated 
with either mouse or human UC, we focused here on 
miR-16 because our previous in vitro data showed that 
Cl-amidine induces miR-16 expression and decreases the 
expression of several miR-16 targets (i.e. Cyclins D1, D2, 
D3, E1, and CDK6) involved in the progression through 
the cell cycle [17]. Likewise, miR-16 is found at lower 
levels in CRC than in normal tissue [36]. One prospective 
pathway through which Cl-amidine may be upregulating 
miR-16 expression levels involves the tumor suppressor 
Figure 5: Proposed mechanism of action for cl-
amidine preventing crc. As evidenced in the results 
produced in this manuscript, Cl-amidine upregulates miR-16 
expression in mice through PAD inhibition. At this point, the 
cell proliferation targets (Cyclin D1 and E1) of miR-16 are 
downregulated, accounting for the decreased tumorigenesis 
found at the endpoint of our study.
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p53. p53 boosts the post-transcriptional maturation of 
miR-16 and Cl-amidine is found to increase miR-16 
expression in a p53-dependent manner in vitro [17, 37-39].
In summary, we have shown that Cl-amidine 
suppresses colitis and, in this current study, suppresses 
tumorigenesis in mice given Cl-amidine dosages in 
drinking water [14]. Our current in vivo study is a 
substantial extension of our previous mechanistic 
in vitro data and suggests that increased miR-16 
expression in mice treated with Cl-amidine results 
in decreased tumor formation [17]. When miR-16 
is downregulated, this relieves its inhibition of cell 
proliferative targets, like Cyclin D1 and E1. Because our 
results demonstrate that Cl-amidine can suppress these 
targets of miR-16, this verifies the activity of miR-16 
throughout our model. These findings display a significant 
development in our knowledge of in vivo mechanisms 
by which PAD inhibition can suppress colon cancer. 
Future studies will explore the mechanism(s) by which 
Cl-amidine is increasing miR-16 expression and will 
determine optimum dosages for preventing tumorigenesis. 
Overall, this study presents Cl-amidine as a viable cancer 
preventative therapy against colitis-associated colorectal 
cancer and provides an innovative mechanism of action 
involving the upregulation of miR-16, ultimately 
leading to decreased cell proliferation and prevention of 
tumorigenesis in vivo.
MAterIAls And Methods
cl-amidine
The synthesis of Cl-amidine has previously been 
described [6, 40].
AoM/dss mouse model of colitis-associated 
colorectal cancer
This mouse model of colorectal cancer is outlined in 
Figure 1A. C57BL/6 male mice (8-12 weeks old; Jackson 
Laboratory) were used in accordance with protocols 
approved by the Institutional Animal Care and Use 
Committees of University of South Carolina. AOM (10 
mg/kg) was injected into each mouse via intraperitoneal 
injection. The mice were divided into four groups where 
Group 1 received drinking water ad libitum throughout 
the experiment. One week after AOM injection, Groups 
2-4 began cycles of 2% DSS (MP Biomedicals, Solon, 
OH; m.w. 36 000 -50 000) given in the drinking water 
for 70 days. Groups 2-4 were subjected to three cycles, 
each consisting of one week with 2% DSS in the water 
followed by two weeks of normal drinking water. The DSS 
cycles were aimed to simulate the active inflammatory and 
remission states of UC. Groups 3 and 4 were administered 
0.05 mg/mL and 0.25 mg/mL Cl-amidine, respectively, 
daily in the drinking water beginning at day 14 and ending 
at day 70.
0.05 mg/mL and 0.25 mg/mL, which is the 
equivalent of 10 mg/kg/day and 50 mg/kg/day per mouse, 
respectively; or the human daily equivalent of 48.6 mg 
and 243 mg, respectively. Calculations are as follows: 
assuming an average mouse weighs 25 g and drinks 
approximately 5 mL per day, then 0.25 mg / 25 g x 1000 
g / 1 kg = 10 mg/kg daily. The human equivalent dose 
(HED, mg/kg) = animal dose (mg/kg) x [Animal Km 
/ Human Km] [41]. The HED (mg/kg) for mouse = 10 
mg/kg x [3/37] = 0.81 mg/kg. Therefore, assuming an 
adult human weighs approximately 60 kg on average, 
the human equivalent is 0.81 mg/kg x 60 kg = 48.6 mg 
daily. Using the same equations, the 0.25 mg/mL mouse 
dosage is approximately the equivalent of 243 mg daily for 
humans. We chose these doses because our previous work 
has shown that 5 - 75 mg/kg/mouse per day was effective 
in a dose-responsive manner at suppressing DSS-induced 
colitis in mice [14]. Since 5 mg/kg/day was only modestly 
effective, and 75 mg/kg/day is the Maximal Tolerable 
Dose, we wanted to investigate the potency of multiple 
doses within this range [14, 15]. Thus we chose 0.05 
mg/mL and 0.25 mg/mL delivered in the drinking water. 
We reasoned Cl-amidine would work better delivered in 
the drinking water because Cl-amidine has a short half-
life in vivo [15]. Therefore delivering the same amount 
throughout the day over a long period of time (in water) 
versus a bolus amount (oral gavage) would be a better 
method with short-life compounds. We also determined 
that Cl-amidine is stable in DSS-spiked water for 48 
h (data not shown) and the mice drink approximately 
the same amount of water daily regardless of treatment 
(Supplementary Figure S1).
At day 35, after 1.5 cycles of DSS, 10 mice from 
each group (1- 4) were euthanized to ensure that the DSS 
was effective and for further analysis. Colons from each 
mouse were removed, cut longitudinally, and washed with 
1x phosphate buffered saline (PBS). The colons from four 
mice from each group were Swiss-rolled, fixed in 10% 
buffered formalin overnight, paraffin embedded, and then 
sectioned for histopathology/immunohistochemistry. The 
colons from the remaining six mice/group were incubated 
in 10% fetal calf serum/5 mM ethylenediaminetetraacetic 
acid (EDTA)/Ca2+/Mg2+ free PBS for 15 min. Colons 
were then shaken gently for 10 sec and the single cell 
suspension, consisting of epithelial and inflammatory 
cells, collected in the supernatant. Inflammatory cells were 
separated from epithelial cells using CD45+ magnetic 
microbeads that select for the inflammatory cells, 
according to kit instructions (mouse CD45+ MicroBeads, 
Miltenyi Biotec, Auburn, CA). These separated cells were 
immediately processed for miRNA analysis to avoid any 
breakdown of the RNA integrity. 
At day 70, the remaining 15 mice from each of 
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the groups were euthanized. Colons were removed, 
cut longitudinally, and washed with 1x PBS. Tumor 
incidence and size were recorded for each colon. Colons 
from each group were processed for histopathology/
immunohistochemistry in the same manner as the colons 
harvested at day 35.
Quantification of inflammation
Colons prepared for histopathology were stained 
with hematoxylin and eosin (H&E). Sectioned H&E 
stained samples were examined microscopically and 
scored as previously described [14]. Briefly, the histology 
score for a sample was determined by adding the scores 
for inflammation severity, inflammation extent, and crypt 
damage; then, multiplying by the score for percent area 
involvement. The inflammation severity was scored 
on a scale of 0-3: 0 (no inflammation), 1 (minimal), 2 
(moderate), and 3 (severe). Inflammation extent was 
scored on a scale of 0-3: 0 (no inflammation), 1 (mucosa 
only), 2 (mucosa and submucosa), and 3 (transmural). 
Crypt damage was scored on a scale of 0-4: 0 (no crypt 
damage), 1 (one-third of crypt damaged), 2 (two-thirds 
damaged), 3 (crypts lost and surface epithelium intact), 
and 4 (crypts lost and surface epithelium lost). Percent 
area involvement was scored on a scale of 0-4: 0 (0% 
involvement), 1 (1-25%), 2 (26-50%), 3 (51-75%), and 
4 (76-100%). The minimum possible score is 0 and the 
maximum possible score is 40. 
Mir-16 expression
Total miRNA was extracted from separated 
inflammatory (CD45+) and epithelial (CD45-) cells 
according to miRNeasy Mini Kit instructions (Qiagen). 
RNA concentration and stability were measured by 
the Nanodrop 2000 (Nanodrop, Wilmington, DE). 10 
ng of total RNA were used to make cDNA using the 
TaqMan MicroRNA Reverse Transcription kit (Applied 
Biosystems, Foster City, CA) according to kit instructions. 
We also used hsa-miRNA-16 primers for miR-16 detection 
and small nuclear protein RNU6B (U6) for normalization 
(Applied Biosystems, Foster City, CA). Quantitative Real-
Time PCR to measure miR-16 and U6 was performed 
using the TaqMan miRNA Assay (Applied Biosystems, 
Foster City, CA) with the 7300 PCR Assay System 
(Applied Biosystems, Foster City, CA). The relative fold 
change (FC) of miR-16 expression, as compared to U6 
expression, was determined based on the comparative 
threshold cycles (Ct) of miR-16 and U6. All samples were 
analyzed in triplicate.
Immunohistochemical staining
Paraffin-embedded sections of mouse colonic tissue 
were incubated (4˚C) in Cyclin D1 (Rabbit monoclonal, 
cat# TA307019, diluted 1:100, Origene, Rockville, 
MD), Cyclin E1 (rabbit polyclonal, cat# TA311853, 
diluted 1:1000, Origene, Rockville, MD), and anti-Ki67 
(Rabbit polyclonal, cat# PA5-19462, diluted 1:5000, 
Pierce, Rockford, IL) primary antibodies by slow rocking 
overnight with Antibody Amplifier (ProHisto, Columbia, 
SC) to ensure even and reproducible staining. Samples 
were then processed using the EnVision+ System HRP kits 
(DAKO, Carpinteria, CA) according to kit instructions. 
The chromagen, diaminobenzidine, was added and 
then the samples were counterstained with methyl 
green. Stained tissues were objectively scored based on 
two criteria: 1) percentage of tissue stained, and 2) the 
staining intensity. The percentage of tissue stained was 
scored on a scale of 0-5: 0 (0% positive staining), 1 ( < 
10%), 2 (11-25%), 3 (26%-50%), 4 (51%-80%), or 5 ( > 
80%). Staining intensity was scored on a scale of 0-3: 0 
(Negative staining), 1 (Weak), 2 (Moderate), or 3 (Strong). 
Scores from each criteria were multiplied to get the final 
immunoreactivity score (IRS).
statistical analysis
Mean differences between groups were compared by 
one-way ANOVA with Scheffe multiple comparison tests. 
The p-value chosen for significance in this study was 0.05.
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